狼瘡治療市場－全球產業規模、佔有率、趨勢、機會和預測，按治療類型、給藥途徑、最終用戶、地區和競爭細分，2020-2030 年預測

2024 年全球狼瘡治療市場價值為 71.2 億美元，預計到 2030 年將達到 107.4 億美元，複合年成長率為 7.09%。這一成長主要歸因於全球紅斑性狼瘡盛行率的上升。紅斑性狼瘡是一種自體免疫疾病，患者免疫系統會攻擊自身的組織和器官。此疾病引起的發炎可影響多個系統，包括關節、皮膚、腎臟、肺臟、心臟和大腦。紅斑性狼瘡的診斷通常很困難，因為其症狀多樣且與其他疾病重疊。在許多情況下，其特徵性症狀是臉頰上出現蝴蝶狀皮疹。雖然有些人有遺傳易感性，但感染、藥物或日光照射也可能引發紅斑性狼瘡。根據美國紅斑狼瘡基金會的數據，全球有超過 500 萬人患有紅斑性狼瘡，主要為 15 至 44 歲的人。

關鍵市場促進因素

系統性紅斑狼瘡（SLE）全球盛行率上升

主要市場挑戰

先進療法成本高且低收入地區難以取得

主要市場趨勢

個人化醫療在狼瘡治療的應用日益廣泛

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：COVID-19 對全球狼瘡治療市場的影響

第6章：臨床試驗分析

第7章：全球狼瘡治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依治療類型（非類固醇抗發炎藥、皮質類固醇、抗瘧藥、免疫抑制劑、生物製劑、其他）
  • 依給藥途徑（口服、靜脈注射、皮下注射）
  • 按最終使用者（醫院和診所、門診護理中心、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按治療類型
  • 依給藥途徑
  • 按最終用戶
  • 按地區

第 8 章：北美狼瘡治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第9章：歐洲狼瘡治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利

第10章：亞太狼瘡治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 11 章：南美洲狼瘡治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 12 章：中東和非洲狼瘡治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第13章：市場動態

• 驅動程式
• 挑戰

第 14 章：市場趨勢與發展

• 產品發布
• 併購
• 最新動態

第 15 章：全球狼瘡治療市場：SWOT 分析

第 16 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 17 章：競爭格局

• GSK plc.
• Novartis AG
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• ImmuPharma PLC
• Pfizer Inc.
• Sanofi SA
• Bristol-Myers Squibb Company
• Merck & Co., Inc.

第 18 章：策略建議

第19章調查會社について,免責事項

The Global Lupus Therapeutics Market was valued at USD 7.12 billion in 2024 and is projected to reach USD 10.74 billion by 2030, growing at a CAGR of 7.09%. This growth is largely attributed to the increasing global prevalence of lupus, an autoimmune condition in which the body's immune system attacks its own tissues and organs. The disease causes inflammation that can affect multiple systems, including the joints, skin, kidneys, lungs, heart, and brain. Diagnosing lupus is often difficult due to its diverse and overlapping symptoms with other conditions. A signature symptom in many cases is a butterfly-shaped rash across the cheeks. While some individuals are genetically predisposed, lupus can also be triggered by infections, medications, or exposure to sunlight. According to the Lupus Foundation of America, over five million people worldwide are affected by lupus, primarily those aged 15 to 44.

Key Market Drivers

Rising Global Prevalence of Systemic Lupus Erythematosus (SLE)

The growing prevalence of systemic lupus erythematosus (SLE), the most common and severe form of lupus, is a significant driver of the lupus therapeutics market. SLE is a chronic autoimmune condition where the immune system mistakenly attacks healthy tissues, resulting in inflammation and organ damage. This condition is especially prevalent among women of reproductive age and is disproportionately seen in African American, Hispanic, and Asian populations. The increasing awareness, improved diagnostic capabilities, and rising incidence of autoimmune disorders globally are collectively contributing to the market's expansion.

Key Market Challenges

High Cost of Advanced Therapies and Limited Access in Low-Income Regions

Despite advancements in treatment, the high cost of biologics and targeted lupus therapies presents a major challenge, particularly in low- and middle-income regions. These innovative drugs, although effective, are often unaffordable for many patients-even in high-income countries with insurance coverage. In regions with limited healthcare infrastructure and funding, access to these treatments remains restricted. The economic burden limits the use of advanced therapeutics, thereby widening the treatment gap. Additionally, constrained healthcare budgets and inadequate reimbursement policies further hinder the adoption of these high-cost medications.

Key Market Trends

Growing Adoption of Personalized Medicine in Lupus Treatment

An emerging trend in the lupus therapeutics market is the growing shift toward personalized medicine. This approach tailors treatment to an individual's genetic, molecular, and phenotypic characteristics. Personalized strategies are especially important in lupus, which is marked by variable symptoms, disease progression, and treatment responses.

Advances in genomics, proteomics, and immunophenotyping are enabling more precise patient stratification and treatment planning. For instance, researchers funded by the NIH have identified immune pathway signatures-such as type I interferon activity-that may help predict patient response to specific biologics. Clinical trials are now being designed with biomarker-driven enrollment to increase efficacy, reduce side effects, and streamline drug approvals.

These innovations are supported by government initiatives such as the FDA's Precision Medicine Initiative and the European Union's Horizon Europe framework, both of which prioritize the development of targeted therapies for complex diseases like lupus.

Key Market Players

• GSK plc.
• Novartis AG
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• ImmuPharma PLC
• Pfizer Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.

Report Scope:

In this report, the Global Lupus Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lupus Therapeutics Market, By Treatment Type:

• NSAIDs
• Corticosteroids
• Antimalarials
• Immunosuppressants
• Biologics
• Others

Lupus Therapeutics Market, By Route of Administration:

• Oral
• Intravenous
• Subcutaneous

Lupus Therapeutics Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Lupus Therapeutics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lupus Therapeutics Market.

Available Customizations:

Global Lupus Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Lupus Therapeutics Market

6. Clinical Trial Analysis

• 6.1. Ongoing Clinical Trials
• 6.2. Completed Clinical Trials
• 6.3. Terminated Clinical Trials
• 6.4. Breakdown of Pipeline, By Development Phase
• 6.5. Breakdown of Pipeline, By Status
• 6.6. Breakdown of Pipeline, By Study Type
• 6.7. Breakdown of Pipeline, By Region
• 6.8. Clinical Trials Heat Map

7. Global Lupus Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others)
  • 7.2.2. By Route of Administration (Oral, Intravenous, Subcutaneous)
  • 7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 7.2.4. By Region
  • 7.2.5. By Company (2024)
• 7.3. Market Map
  • 7.3.1. By Treatment Type
  • 7.3.2. By Route of Administration
  • 7.3.3. By End User
  • 7.3.4. By Region

8. North America Lupus Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Lupus Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By End User
  • 8.3.2. Canada Lupus Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By End User
  • 8.3.3. Mexico Lupus Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By End User

9. Europe Lupus Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Europe: Country Analysis
  • 9.3.1. Germany Lupus Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By End User
  • 9.3.2. France Lupus Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By End User
  • 9.3.3. United Kingdom Lupus Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By End User
  • 9.3.4. Spain Lupus Therapeutics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment Type
      • 9.3.4.2.2. By Route of Administration
      • 9.3.4.2.3. By End User
  • 9.3.5. Italy Lupus Therapeutics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Treatment Type
      • 9.3.5.2.2. By Route of Administration
      • 9.3.5.2.3. By End User

10. Asia-Pacific Lupus Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. Asia-Pacific: Country Analysis
  • 10.3.1. China Lupus Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By End User
  • 10.3.2. India Lupus Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By End User
  • 10.3.3. Japan Lupus Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By End User
  • 10.3.4. South Korea Lupus Therapeutics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Treatment Type
      • 10.3.4.2.2. By Route of Administration
      • 10.3.4.2.3. By End User
  • 10.3.5. Australia Lupus Therapeutics Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Treatment Type
      • 10.3.5.2.2. By Route of Administration
      • 10.3.5.2.3. By End User

11. South America Lupus Therapeutics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Treatment Type
  • 11.2.2. By Route of Administration
  • 11.2.3. By End User
  • 11.2.4. By Country
• 11.3. South America: Country Analysis
  • 11.3.1. Brazil Lupus Therapeutics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Treatment Type
      • 11.3.1.2.2. By Route of Administration
      • 11.3.1.2.3. By End User
  • 11.3.2. Argentina Lupus Therapeutics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Treatment Type
      • 11.3.2.2.2. By Route of Administration
      • 11.3.2.2.3. By End User
  • 11.3.3. Colombia Lupus Therapeutics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Treatment Type
      • 11.3.3.2.2. By Route of Administration
      • 11.3.3.2.3. By End User

12. Middle East and Africa Lupus Therapeutics Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Treatment Type
  • 12.2.2. By Route of Administration
  • 12.2.3. By End User
  • 12.2.4. By Country
• 12.3. MEA: Country Analysis
  • 12.3.1. South Africa Lupus Therapeutics Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Treatment Type
      • 12.3.1.2.2. By Route of Administration
      • 12.3.1.2.3. By End User
  • 12.3.2. Saudi Arabia Lupus Therapeutics Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Treatment Type
      • 12.3.2.2.2. By Route of Administration
      • 12.3.2.2.3. By End User
  • 12.3.3. UAE Lupus Therapeutics Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Treatment Type
      • 12.3.3.2.2. By Route of Administration
      • 12.3.3.2.3. By End User

13. Market Dynamics

• 13.1. Drivers
• 13.2. Challenges

14. Market Trends & Developments

• 14.1. Product Launches
• 14.2. Mergers & Acquisitions
• 14.3. Recent Developments

15. Global Lupus Therapeutics Market: SWOT Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. GSK plc.
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (As Reported)
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel Details
  • 17.1.7. SWOT Analysis
• 17.2. Novartis AG
• 17.3. AstraZeneca
• 17.4. F. Hoffmann-La Roche Ltd
• 17.5. Eli Lilly and Company
• 17.6. ImmuPharma PLC
• 17.7. Pfizer Inc.
• 17.8. Sanofi S.A.
• 17.9. Bristol-Myers Squibb Company
• 17.10. Merck & Co., Inc.

18. Strategic Recommendations

19. About Us & Disclaimer